NVCT

MKT CAP:$236M

Nuvectis Pharma, Inc.

Market Cap

$236M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.79+$0.28 (+3.29%)

Apr 23, 2026

Company Details

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the tr...

CEO

Ron Bentsur

IPO Date

Feb 4, 2022

Website

www.nuvectis.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$25M

EPS (Diluted)

-$1.22

Free Cash Flow

-$14M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 11, 2026

$0EPS -$1.32

Q4 2025

Feb 11, 2026

$0EPS -$0.31

Q2 2025

Aug 5, 2025

$0EPS -$0.30

Q1 2025

May 6, 2025

$0EPS -$0.27

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$2M
Q1 22	$0	$0	-$3M
Q2 22	$0	$0	-$4M
Q3 22	$0	$0	-$6M
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$4M
Q2 23	$0	$0	-$6M
Q3 23	$0	$0	-$6M
Q4 23	$0	$0	-$7M
Q1 24	$0	$0	-$4M
Q2 24	$0	$0	-$5M
Q3 24	$0	$0	-$4M
Q4 24	$0	$0	-$6M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$7M
Q4 25	$0	$0	-$8M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$1M	-$1M
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$3M
Q3 22	-$4M	-$4M
Q4 22	-$4M	-$4M
Q1 23	-$5M	-$5M
Q2 23	-$4M	-$4M
Q3 23	-$3M	-$3M
Q4 23	-$4M	-$4M
Q1 24	-$4M	-$4M
Q2 24	-$3M	-$3M
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$4M	-$4M
Q2 25	-$3M	-$3M
Q4 25	-$4M	-$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+12704.3%
Q2 22	—	-39.8%
Q3 22	—	+27.2%
Q4 22	—	+199.2%
Q1 23	—	+39.3%
Q2 23	—	+61.5%
Q3 23	—	+3.7%
Q4 23	—	+1.3%
Q1 24	—	+7.2%
Q2 24	—	-19.6%
Q3 24	—	-29.2%
Q4 24	—	-6.1%
Q1 25	—	+26.7%
Q2 25	—	+42.0%
Q4 25	—	+74.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$185.0K	—
Q1 22	$156.0K	—
Q2 22	$510.0K	—
Q3 22	$559.0K	—
Q4 22	$482.0K	—
Q1 23	$1M	—
Q2 23	$950.0K	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$1M	—
Q4 24	$1M	—
Q1 25	$1M	—
Q2 25	$2M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$1M	$1M
Q1 22	$2M	$1M
Q2 22	$3M	$1M
Q3 22	$5M	$1M
Q4 22	$4M	$2M
Q1 23	$2M	$2M
Q2 23	$4M	$2M
Q3 23	$4M	$2M
Q4 23	$4M	$3M
Q1 24	$3M	$2M
Q2 24	$3M	$2M
Q3 24	$3M	$2M
Q4 24	$4M	$2M
Q1 25	$4M	$2M
Q2 25	$4M	$3M
Q4 25	$5M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$17M	$0	$17M
Q2 22	$14M	$0	$14M
Q3 22	$24M	$0	$24M
Q4 22	$20M	$0	$20M
Q1 23	$15M	$0	$15M
Q2 23	$25M	$0	$25M
Q3 23	$22M	$0	$22M
Q4 23	$19M	$0	$19M
Q1 24	$19M	$0	$19M
Q2 24	$18M	$0	$18M
Q3 24	$17M	$0	$17M
Q4 24	$19M	$0	$19M
Q1 25	$30M	$0	$30M
Q2 25	$27M	$0	$27M
Q3 25	$35M	$0	$35M
Q4 25	$32M	$0	$32M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	13M	0.0%	—
Q1 22	13M	0.0%	0.0%
Q2 22	13M	0.0%	0.0%
Q3 22	14M	+10.5%	+10.5%
Q4 22	15M	+4.2%	+15.1%
Q1 23	15M	+0.6%	+15.8%
Q2 23	15M	+3.1%	+19.3%
Q3 23	16M	+6.1%	+14.6%
Q4 23	17M	+8.2%	+19.0%
Q1 24	17M	-4.9%	+12.5%
Q2 24	17M	+2.1%	+11.3%
Q3 24	17M	+2.0%	+7.0%
Q4 24	19M	+13.1%	+11.9%
Q1 25	20M	+2.3%	+20.4%
Q2 25	21M	+7.2%	+26.4%
Q4 25	22M	+2.1%	+26.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	8
Q1 22	$0	8
Q2 22	$0	8
Q3 22	$0	8
Q4 22	$0	11
Q1 23	$0	11
Q2 23	$0	11
Q3 23	$0	11
Q4 23	$0	13
Q1 24	$0	13
Q2 24	$0	13
Q3 24	$0	13
Q4 24	$0	13
Q1 25	$0	13
Q2 25	$0	13
Q4 25	$0	13

Revenue / Employee